Arca
Skip to content
Tools
Tools

Urticaria

Drug research and approvals for urticaria: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 60 studies of urticaria are recruiting on ClinicalTrials.gov, Health Canada has authorized 32 drug trials for it since 2013, FDA has 0 approved and 1 open orphan designations naming it, and the EU has 8 authorised medicines for it.

  • Recruiting worldwide: 60
  • Trials authorized in Canada: 32
  • FDA orphan approvals: 0
  • EU medicines: 8

Recruiting now

Newest posted first, of 60 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 14

Phase 3 6

Phase 2 11

Phase 1 or earlier 4

How its trials ended

249 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 69 whose ending is known, 48% met their primary endpoint, 4% missed it and 48% stopped early.

  • Completed, result not reported11245%
  • Ongoing4217%
  • Met its primary endpoint3313%
  • Status unknown2610%
  • Stopped: other or unclear146%
  • Stopped: enrollment or feasibility73%
  • Stopped: sponsor or business decision62%
  • Stopped: lack of efficacy52%
  • Missed its primary endpoint31%
  • Stopped: funding1<1%

Trials authorized in Canada

The 10 newest of 32; search them all in Canada trials
Feb 27, 2026A phase 3b long-term efficacy and safety extension study of barzolvolimab in participants with chronic spontaneous urticaria who have completed CDX0159-12 or…Barzolvolimab (CDX-0159)Celldex Therapeutics IncOngoing
Apr 2, 2025A randomized, double-blind, placebo controlled, dose-ranging study evaluating the efficacy and safety of EVO756 in adults with moderate to severe chronic…EVO756EvommuneClosed
Oct 10, 2024A phase 3 randomized, double-blind, placebo-controlled study to assess the efficacy and safety of barzolvolimab in patients with chronic spontaneous urticaria…Barzolvolimab (CDX-0159)Celldex Therapeutics IncOngoing
Oct 4, 2024A phase 3 randomized, double-blind, placebo-controlled study to assess the efficacy and safety of barzolvolimab in patients with chronic spontaneous urticaria…CDX-0159Celldex Therapeutics IncOngoing
Aug 2, 2024An open-label extension study evaluating the safety, tolerability, pk, immunogenicity, and clinical response of multiple doses of iv AK006 in subjects with H1…AK006AllakosOngoing
Feb 8, 2024A phase 1, double-blind, randomized, placebo-controlled, sequential, singleand multiple- ascending dose study to evaluate the safety, tolerability, pk, and…AK006AllakosClosed
Nov 20, 2023A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and…Remibrutinib (LOU064)Novartis PharmaceuticalsOngoing
Aug 18, 2023A global, multicenter, randomized, double-blind, double-dummy, parallel-group, phase 3b study to assess the efficacy, safety, and tolerability of remibrutinib…Remibrutinib (LOU064)Novartis PharmaceuticalsOngoing
Aug 15, 2023Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the effects of EP262 in subjects with chronic spontaneous urticariaEP262Escient Pharmceuticals IncClosed
Aug 10, 2023Phase 1b, open-label study to evaluate the safety, tolerability, and pharmacodynamics of EP262 in subjects with chronic inducible urticariaEP262Escient Pharmceuticals IncClosed

FDA orphan designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Dec 11, 2009AfamelanotideTreatment of solar urticariaClinuvel, Inc.Designated

Medicines authorised in the EU

Newest first
Apr 23, 2026RhapsidoRemibrutinibNovartis Europharm LimitedEMA ↗
Jan 13, 2012Desloratadine ActavisDesloratadine · genericActavis Group PTC ehfEMA ↗
Jan 13, 2012Desloratadine ratiopharmDesloratadine · genericRatiopharm GmbHEMA ↗
Nov 28, 2011DasseltaDesloratadine · genericKRKA tovarna zdravil d.d. Novo mestoEMA ↗
Nov 24, 2011Desloratadine TevaDesloratadine · genericTeva B.VEMA ↗
Jan 15, 2001AeriusDesloratadineOrganon N.V.EMA ↗
Jan 15, 2001NeoclaritynDesloratadineOrganon N.V.EMA ↗
Jan 15, 2001AzomyrDesloratadineOrganon N.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.